Omar N I, Baharin B, Lau S F, Ibrahim N, Mohd N, Ahmad Fauzi A, Muhammad N, Fernandez N M
Unit of Periodontology, Department of Restorative Dentistry, Faculty of Dentistry, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Faculty of Veterinary Medicine, Universiti Putra Malaysia, Seri Kembangan, Selangor Darul Ehsan, Malaysia.
Vet Med Int. 2020 Dec 24;2020:8862489. doi: 10.1155/2020/8862489. eCollection 2020.
has been shown to possess antioxidant properties that could prevent the development of chronic inflammatory bone diseases. In this study, the efficacy of in preventing alveolar bone resorption in osteoporotic rats induced by ovariectomy (OVX) was investigated. Twenty-four female Wistar rats were divided into four groups ( = 6) consisting of sham-operated (SO), ovariectomized control (OVXN), ovariectomized treated with estrogen (OVXP), and ovariectomized treated with extract (OVXF). At the beginning of the study, two nonovariectomized, healthy rats were sacrificed to serve as baseline (BL). Treatment of the rats commenced two weeks after ovariectomy-the OVXP rats that served as positive control received Premarin® (64.5 g/kg body weight), while OVXF rats were given (800 mg/kg body weight); both agents were administered orally for two months. The negative control group of rats (OVXN) and the SO group received deionized water, also administered via oral gavage. At necropsy, morphometric assessment of the interradicular bone of the first molar was carried out using a micro-CT scanner, while quantification of osteoclasts and osteoblasts was performed histologically. The results showed that no statistically significant differences among the groups ( > 0.05) for bone morphometric assessment. However, trabecular thickness in the OVXF group was similar to BL, while trabecular separation and alveolar bone loss height were lower than those of the OVXN group. Histologically, the OVXF group demonstrated a significantly lower number of osteoclasts and a higher number of osteoblasts compared with OVXN (=0.008 and =0.019, respectively; < 0.05). In conclusion, has the capacity to prevent alveolar bone loss in ovariectomy-induced osteoporosis rats by potentially preserving trabecular bone microarchitecture and to decrease osteoclast and increase osteoblast cell count.
已被证明具有抗氧化特性，可预防慢性炎症性骨病的发展。在本研究中，研究了其在预防去卵巢（OVX）诱导的骨质疏松大鼠牙槽骨吸收方面的功效。将24只雌性Wistar大鼠分为四组（每组n = 6），包括假手术组（SO）、去卵巢对照组（OVXN）、去卵巢雌激素治疗组（OVXP）和去卵巢提取物治疗组（OVXF）。在研究开始时，处死两只未去卵巢的健康大鼠作为基线（BL）。去卵巢两周后开始对大鼠进行治疗——作为阳性对照的OVXP组大鼠接受倍美力®（64.5μg/kg体重），而OVXF组大鼠给予（800mg/kg体重）；两种药物均口服给药两个月。大鼠阴性对照组（OVXN）和SO组接受去离子水，也通过灌胃给药。尸检时，使用微型CT扫描仪对第一磨牙根间骨进行形态计量评估，同时组织学定量破骨细胞和成骨细胞。结果显示，各组间骨形态计量评估无统计学显著差异（P>0.05）。然而，OVXF组的小梁厚度与BL组相似，而小梁间距和牙槽骨丧失高度低于OVXN组。组织学上，与OVXN组相比，OVXF组破骨细胞数量显著减少，成骨细胞数量增加（分别为P = 0.008和P = 0.019；P<0.05）。总之，通过潜在地保留小梁骨微结构，有能力预防去卵巢诱导的骨质疏松大鼠的牙槽骨丧失，并减少破骨细胞数量和增加成骨细胞数量。
